From Financial Modeling Prep: 2025-05-14 16:00:00

MannKind Corporation (NASDAQ:MNKD) specializes in inhaled therapeutic products for diabetes patients, with Afrezza as its key product for controlling blood sugar levels in adults. The company competes with Geron, Celldex, ACADIA, Amarin, and Exelixis. MannKind’s ROIC of 21.29% and WACC of 11.91% result in a strong ROIC to WACC ratio of 1.79, indicating efficient capital utilization.

Compared to MannKind, Geron has a negative ROIC of -26.79% and a WACC of 8.74%, resulting in a concerning ROIC to WACC ratio of -3.07. Celldex and Amarin also show inefficiencies with negative ratios of -2.04 and -2.70, respectively. In contrast, ACADIA boasts a ROIC to WACC ratio of 3.82, while Exelixis performs well with a ratio of 3.45.

While MannKind’s ROIC to WACC ratio of 1.79 is positive, ACADIA and Exelixis outperform it with higher ratios. However, MannKind’s ability to generate returns above its cost of capital remains a positive aspect compared to peers with negative ratios. Investors may find the company’s efficient capital utilization appealing in the competitive landscape.



Read more at Financial Modeling Prep:: MannKind Corporation’s Financial Performance in th…